Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male, aged 12 to 65 years~* Severe hemophilia A defined as \< 1% FVIII:C~* \>/= 150 days of previous treatment with FVIII in lifetime~* Currently receiving on-demand or any type of prophylaxis treatment regimen with any FVIII product~* No history of or current FVIII inhibitors~Exclusion Criteria:~* Presence of another bleeding disease that is different from hemophilia A (e.g., von Willebrand disease, hemophilia B)~* Low platelet count, abnormal kidney function, or liver disease~* Received treatment with immune suppressing drugs within the last 3 months prior or requires treatment during the study. (Some drugs for hepatitis C, Human immunodeficiency virus (HIV), and steroids are allowed)~* Receiving or has received other experimental drugs within 3 months prior to study entry~* Allergy to Factor VIII or hamsters or mouse protein

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Recombinant Factor VIII (BAY81-8973) then Kogenate FS (Type: EXPERIMENTAL): Part A - Arm 1: Participants first received one single intravenous (IV) injection of BAY81-8973 50 IU/kg, then 1 single IV injection of Kogenate FS (BAY14-2222) 50 IU/kg with a wash-out period of at least 2-3 days in between
- Arm 2: Kogenate FS then Recombinant Factor VIII (BAY81-8973) (Type: EXPERIMENTAL): Part A - Arm 2: Participants first received one single intravenous (IV) injection of Kogenate FS (BAY14-2222) 50 IU/kg, then 1 single IV injection of BAY81-8973 50 IU/kg with a wash-out period of at least 2-3 days in between
- Arm 3: Recombinant Factor VIII by CS/EP then by CS/ADJ (Type: EXPERIMENTAL): Part B - Arm 3: Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months
- Arm 4: Recombinant Factor VIII by CS/ADJ then by CS/EP (Type: EXPERIMENTAL): Part B - Arm 4:. Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay Per European Pharmacopeia for 6 months
- Arm 5: Recombinant Factor VIII by CS/EP (Type: EXPERIMENTAL): Part C - Arm 5: Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete